Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 170,452

Document Document Title
WO/2018/221550A1
Provided is a therapeutic agent for Alzheimer's disease. The therapeutic agent combines: (I) (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofura n-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one, which is represented by formula (I), ...  
WO/2018/221545A1
Provided is a therapeutic agent for Alzheimer's disease and dementia with Lewy bodies. The therapeutic agent combines: (I) (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofura n-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one, which i...  
WO/2018/221679A1
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.  
WO/2018/221562A1
According to the present invention, it is found that dopamine D2-like receptor agonists acts on a dopamine D2-like receptor in an activated Th cell and thereby inhibits the production of Interleukin-8 (IL-8).  
WO/2018/220068A1
The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the prevention or treatment of a disease associated with a dysregulation of the mTOR p...  
WO/2018/221555A1
A method for predicting the therapeutic effect of chemotherapy using an anti-tumor agent containing an LSD1 inhibitor in a cancer patient, on the basis of the expression level of INSM1 in a sample including tumor cells collected from the...  
WO/2018/221627A1
A purslane processed material characterized by being obtained by adding yeast to a hot-water extract obtained by treating purslane by hot water, and culturing the yeast.  
WO/2018/221291A1
[Problem] Various side effects have been reported for conventional therapeutic drugs for hyperactive bladder, and a prophylactic or therapeutic agent for hyperactive bladder without causing side effects is desired. [Solution] Provided is...  
WO/2018/216659A1
[Problem] The purpose of the present invention is to provide an emulsion composition which contains glycyrrhetinic acid, glycyrrhizic acid and derivatives and/or salts thereof, and ufenamate, and is prevented from the formation of precip...  
WO/2018/216800A1
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...  
WO/2018/216795A1
An anti-cancer agent containing a biphenyl compound represented by general formula (I) [wherein ring A, ring B, R1 to R6, l, m and n are as defined in the description] and having a LSD1-inhibiting activity or a salt thereof and another a...  
WO/2018/215628A1
The present invention relates to a sulfonylurea compound for use in the treatment and/or amelioration of a disease that is associated with UV-induced DNA damage, wherein the subject to be treated expresses enzymatically active mutY homol...  
WO/2018/216640A1
Provided is a drug having as an active ingredient thereof a compound having antagonistic activity against an EP4 receptor in the prophylaxis and/or treatment of diseases attributed to the activation of the EP4 receptor. A compound repres...  
WO/2018/215795A2
The present invention relates to an agent for use in selectively killing one or more senescent cells, wherein said agent is selected from the following: a cardiac glycoside or alglycone, a focal adhesion kinase (FAK) inhibitor, an HMG-Co...  
WO/2018/216821A1
An object of the present invention is to provide a measure for treating or preventing a disease or condition that involves AMPK dysregulation, particularly diabetes, obesity, and hyperlipidemia. The present invention provides a combinati...  
WO/2018/216744A1
The present invention addresses the problem of providing a cosmetic and a skin protecting agent by which the balance of skin indigenous bacteria can be improved and, preferably, the ratio of Staphylococcus epidermidis, which is a useful ...  
WO/2018/213340A1
Provided are a recombinant acid α-glucosidase and pharmaceutical composition comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an in...  
WO/2018/213151A1
This disclosure relates to stable aqueous pharmaceutical formulations comprising a therapeutically effective amount of an incretin-insulin conjugate as well as methods of using the same, and aqueous pharmaceutical formulations containing...  
WO/2018/212363A1
An object of the present invention is to provide a measure for treating or preventing a disease or condition that involves AMPK dysregulation, particularly a cancer. The present invention provides a combination therapy using a compound p...  
WO/2018/212362A1
The problem to be solved is to suppress carbohydrate breakdown and absorption in the body in order to suppress the blood sugar level, and to provide long-term prevention and amelioration of diabetes and obesity derived from hyperglycemic...  
WO/2018/211742A1
A mask for activating the brain according to the present invention is characterized by being impregnated with an aqueous lemon grass extract which is extracted by an extraction method including the step of stirring lemon grass with stirr...  
WO/2018/212152A1
[Problem] To provide an ophthalmic composition that is efficacious for preventing or treating myopia or ophthalmic diseases. In particular, to provide: an ophthalmic composition that is efficacious for growing children and young adults, ...  
WO/2018/211510A1
Methods of treating an aging-associated disease, as well as inhibiting aging in a subject, by administering pharmaceutical compositions comprising unmodified and modified MSCs and their exosomes are provided.  
WO/2018/212250A1
The purpose of the present invention is to provide an exosome production promoter with which exosome production can be easily promoted. The exosome production promoter contains ceramide as an active ingredient.  
WO/2018/212136A1
The present invention addresses the problem of providing: an antibody having an internalization activity of binding to CDH6; an antibody-drug conjugate consisting of the aforesaid antibody and a drug having an antitumor activity; a medic...  
WO/2018/212237A1
Provided are: a method for determining whether a subject suffering from a brain tumor is an eligible person for a tailor-made type peptide vaccine agent including at least one peptide antigen; a kit used for said determining method; and ...  
WO/2018/207918A1
Provided is a method for easily and highly efficiently purifying and concentrating mesenchymal stem cells (MSC). More specifically, mesenchymal stem cells (MSC) can be easily and highly efficiently purified and concentrated by separating...  
WO/2018/207792A1
Provided is a substance that suppresses a breakage of the blood-brain barrier. A Claudin-5 expression promoter that comprises chlorogenic acid or a salt thereof as an active ingredient. A brain HMGB1 expression inhibitor that comprises c...  
WO/2018/207791A1
Provided is an Arc expression promoter that has a high safety and can be continuously taken. The Arc expression promoter comprises chlorogenic acid or a salt thereof as an active ingredient.  
WO/2018/207741A1
The purpose of the present invention is to provide drugs which are capable of promoting the biosynthesis of PGC-1α participating in energy production or inhibiting slow-to-fast muscle conversion caused by, for example, lack of exercise,...  
WO/2018/206959A1
The present invention relates to orexin receptor antagonists, pharmaceutical compositi comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists as m...  
WO/2018/206956A1
The present invention relates to orexin receptor antagonists, pharmaceutical compositions comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists a...  
WO/2018/207638A1
The problem of providing a novel molecule having high specificity to CLDN-5 and capable of recognizing an extracellular domain of CLDN-5 can be solved by an antibody capable of specifically recognizing the three-dimensional structure or ...  
WO/2018/207099A1
The invention concerns the use of LIK066 in the treatment, prevention or delay of polycystic ovary syndrome.  
WO/2018/207729A1
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has the potential to be used as a therapeutic agent for essential tremor, small fiber neuropathy, dystonia, epilepsy associated with Alzheimer's disease,...  
WO/2018/207881A1
To provide a compound that can exert a BET family protein-inhibiting effect and is likely to be useful as a prophylactic or therapeutic agent for autoimmune diseases and/or inflammatory diseases (for example, rheumatoid arthritis, multip...  
WO/2018/207910A1
The purpose of the present invention is to provide a composition which has an anti-inflammatory effect. An anti-inflammatory composition according to the present invention contains a compound represented by formula 1 as an active ingredi...  
WO/2018/207812A1
The purpose of the present invention is to provide therapeutic agents for bedsore and skin wound and methods for treating bedsore and skin wound. The present invention provides a bedsore therapeutic agent or a bedsore treatment method or...  
WO/2018/207950A1
Provided are a novel class A GPCR antagonist, a production method for same, and a novel compound which interacts with the binding site of a class A GPCR Na+- water molecule cluster. A compound, or a salt thereof, having a structure in wh...  
WO/2018/207900A1
Provided is an NK cell having a higher cytotoxic activity. The purpose of the present invention is to provide a pharmaceutical composition for NK cell therapy that is expected to exhibit improved effects. The present invention provides a...  
WO/2018/207808A1
In order to solve the problem of difficulty of acquisition in neural stem cells and establish a novel treatment means using neural stem cells, the present invention provides a cell formulation which is for treating a brain tumor and is u...  
WO/2018/204762A1
The present invention relates to methods and compositions for developing a hematopoietic cell system to model diseases. These models are used to determine the efficacy of compounds to treat the disease.  
WO/2018/203564A1
Provided is an inhibitor of at least one type of kinase selected from the group consisting of CDK7, CDK4, CDK6, PIM2、TSSK3, MST4, NEK6, MAP3K, MST3, DDR1, SPHK1, CaMK1, AurA, BRK, CaMK4, and PIM1, the inhibitor containing, as an active...  
WO/2018/203499A1
Provided is a pharmaceutical composition including a supernatant of a culture medium that has been used for maintenance culture of stem cells in an undifferentiated state. The stem cells for the pharmaceutical composition may be pluripot...  
WO/2018/201574A1
A traditional Chinese medicine composition for treating rectal prolapse, prepared by employing the following ingredients: 3-9 g of Radix Glycyrrhizae, 6-12 g of Herba Ardisiae Punctatae, 10-20 g of Sixangular Dysosma Rhizome, 3-9 g of He...  
WO/2018/203559A1
Provided are: pharmaceutical compositions for polyglutamine diseases and the uses thereof; methods for prevention, amelioration, progress-suppression and/or treatment of polyglutamine diseases using such pharmaceutical compositions; and ...  
WO/2018/200606A1
Methods for providing wound healing compositions that include umbilical cord blood derived monocytes and umbilical cord blood derived platelet rich plasma are provided. Methods for treating a non-healing wound in a subject by administrat...  
WO/2018/199121A1
The purpose of the present invention is to provide a therapeutic agent which is for inflammatory bowel disease and exhibits superior prophylactic or therapeutic effects on inflammatory bowel disease by using iR-29a and/or miR-29b. The pr...  
WO/2018/199748A1
The present invention pertains to a calcium binder for use in improving perinatal survival in the offspring of a sow, and in reducing or preventing stillbirth of piglets. The invention also pertains to compositions comprising a calcium b...  
WO/2018/200680A1
The present invention relates, in certain embodiments, to methods for preventing and/or treating neurodegenerative damage (e.g., secondary cascade of neurodegenerative damage) and improving functional outcomes (e.g., outcomes associated ...  

Matches 1 - 50 out of 170,452